BofA starts bullish Alvotech coverage on biosimilar launch cycle
BofA initiated coverage of Alvotech with a 'buy' rating and $7 price target, citing FDA approval and upcoming biosimilar launches. The stock rose 2.7% in pre-market trading. BofA forecasts 2026 EPS of $0.01, below consensus, and expects profitability growth through 2028. Key risks include regulatory delays and IP disputes.
How this was made
The 30-second read
Why it matters
The new coverage could attract institutional buying and support the stock's near‑term rally.
Market read
Analyst initiation provides fresh actionable insight for traders focusing on biotech and biosimilar stocks.
What to watch
Potential delays in regulatory approvals and competitive pressure from other biosimilar makers.
Background
Alvotech recently cleared an FDA inspection, removing a regulatory overhang and entering a key launch cycle.
Ticker impact
BofA initiated coverage with a buy rating and $7 price target, lifting the stock 2.7% pre‑open.
Potential further price appreciation toward the $7 target.
Coverage is new, price target is substantially above current price, and the catalyst is immediate.
Market effects
Positive signal for the biosimilar sector as a leading developer receives upgraded coverage.
May boost investor interest in Nordic biotech listings.
Limited to biotech investors; no broad market effect.
Counterpoint
The company still carries $2B cumulative losses and IP litigation risk, which could limit upside.
Key entities
- AnalystBofA Securities
Initiated coverage with a buy rating and $7 price objective.
- CompanyAlvotech S.A.
Biosimilar developer with upcoming US launches of Simponi, Eylea SD, and Entyvio.
